Cassava Sciences Files 8-K: Director Changes & Officer Compensation Updates
Ticker: FLNA · Form: 8-K · Filed: Jul 17, 2024 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 8-K |
| Filed Date | Jul 17, 2024 |
| Risk Level | medium |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $1.23 million, $500, $0.5 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-compensation, board-changes
Related Tickers: SAVA
TL;DR
Cassava Sciences 8-K: Board shakeup, exec pay changes, and other disclosures filed July 15.
AI Summary
On July 15, 2024, Cassava Sciences, Inc. filed an 8-K report detailing several key events. These include the departure of a director, the election of new directors, and updates to compensatory arrangements for certain officers. The filing also addresses Regulation FD disclosures and other material events, along with financial statements and exhibits.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — The filing involves changes in corporate governance and executive compensation, which can introduce uncertainty and affect investor sentiment.
Key Players & Entities
- Cassava Sciences, Inc. (company) — Registrant
- July 15, 2024 (date) — Date of earliest event reported
FAQ
Who departed as a director from Cassava Sciences?
The filing indicates the departure of a director, but the specific name is not provided in the summary information.
Were new directors elected to the board?
Yes, the filing states that new directors were elected.
What other items are covered in the 8-K filing?
The filing also covers Regulation FD disclosures, other events, and financial statements and exhibits.
What is the date of the earliest event reported in this 8-K?
The date of the earliest event reported is July 15, 2024.
What is the standard industrial classification for Cassava Sciences?
The standard industrial classification for Cassava Sciences is Pharmaceutical Preparations [2834].
Filing Stats: 1,565 words · 6 min read · ~5 pages · Grade level 10.2 · Accepted 2024-07-17 09:15:31
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value SAVA Nasdaq Capital Marke
- $1.23 million — receive severance compensation equal to $1.23 million over twelve months following the Effect
- $500 — ness reputation. Dr. Burns will be paid $500 per hour for such consulting services,
- $0.5 million — receive severance compensation equal to $0.5 million in quarterly installments over twelve m
Filing Documents
- sava20240717_8k.htm (8-K) — 42KB
- ex_699380.htm (EX-99.1) — 17KB
- 0001437749-24-022876.txt ( ) — 217KB
- sava-20240715.xsd (EX-101.SCH) — 4KB
- sava-20240715_def.xml (EX-101.DEF) — 14KB
- sava-20240715_lab.xml (EX-101.LAB) — 18KB
- sava-20240715_pre.xml (EX-101.PRE) — 14KB
- sava20240717_8k_htm.xml (XML) — 5KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure On July 17, 2024, Cassava issued a press release related to the matters described in Items 5.02 and 8.01 of this Current Report on Form 8-K. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated into this Item 7.01 by reference. The information furnished in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed to be "filed" for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended (the " Exchange Act "), or otherwise subject to the liabilities of such section, nor shall such information be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Other Events
Item 8.01. Other Events. On July 16, 2024, Cassava and Lindsay Burns, Ph.D., SVP, Neuroscience, at the Company, agreed that Dr. Burns will step down from her employment with the Company, effective immediately. The terms of Dr. Burns' separation are set forth in a Consulting Agreement (the " Burns Agreement "), which includes a Release Agreement, between Dr. Burns and the Company, dated July 16, 2024. Pursuant to the Burns Agreement, following her separation from the Company and for a one-year period, Dr. Burns will furnish consulting services as, and to the extent, reasonably requested by Cassava for purposes of providing information and support for scientific research and/or obtaining governmental approval for the Company's products. Cassava may, in its sole discretion, extend the term of the Burns Agreement for up to an additional year. The Company may also terminate the Burns Agreement at any time for cause, including, without limitation, for any actions that discredit Cassava's business reputation. Dr. Burns will be paid $500 per hour for such consulting services, which will constitute continuous service for purposes of outstanding equity awards held by Dr. Burns. Pursuant to the Burns Agreement, Dr. Burns will receive severance compensation equal to $0.5 million in quarterly installments over twelve months, together with accrued salary through July 16, 2024. Dr. Burns will continue to participate in the Company's medical plan at Cassava's expense for a period of twelve months following separation, which may be extended to eighteen months in connection with an extension of the term of the Burns Agreement. Dr. Burns will remain eligible for applicable indemnification rights under Dr. Burns' existing indemnification agreement, the Company's by-laws and the Company's insurance policies, in each case, subject to the terms and conditions and limitations thereof. The Burns Agreement provides for Dr. Burns' general release of claims in favor of the Company, subjec